Price Alert

AnaptysBio Inc. (ANAB)

NASDAQ: ANAB · Real-Time Price · USD

21.90

0.81 (3.84%)

At close: Sep 05, 2025, 3:59 PM

21.90

0.00%

After-hours: Sep 05, 2025, 04:34 PM EDT

3.84% (1D)

Bid	19.2
Market Cap	613.13M
Revenue (ttm)	123.16M
Net Income (ttm)	-132.59M
EPS (ttm)	-4.1
PE Ratio (ttm)	-5.34
Forward PE	-4.76
Analyst	Buy

Ask	24.15
Volume	340,584
Avg. Volume (20D)	503,127
Open	21.14
Previous Close	21.09
Day's Range	20.61 - 22.30
52-Week Range	12.21 - 40.70
Beta	-0.19

About ANAB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ANAB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ANAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

AnaptysBio Inc. is scheduled to release its earnings on Nov 4, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+7.59%

AnaptysBio shares are trading higher after the com... Unlock content with Pro Subscription

5 months ago

+9.54%

AnaptysBio shares are trading higher after the company announced a $75 million share buyback program.

News

1 month ago · fool.com

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

1 month ago · zacks.com

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $1.71 per share a year ago.

2 months ago · seekingalpha.com

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

Rosnilimab's strong Phase IIb RA data shows sustained efficacy and safety, positioning it as a potential blockbuster in a massive RA market. Despite JNJ's class setback, AnaptysBio offers significant ...

3 months ago · seekingalpha.com

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

AnaptysBio, Inc.'s rosnilimab showed strong phase 2b results in moderate-to-severe RA, achieving key efficacy and safety endpoints, supporting its potential in a $20B U.S. market. Rosnilimab is also b...